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SHORT COMMUNICATION
Clinically relevant concentrations of verapamil do not enhance the
sensitivity of human bone marrow CFU-GM to adriamycin and VP16
M.A. Smithlt, S. Merry2, J.G. Smith' * & S.B. Kaye2
1University Department of Haematology, Western Infirmary, Glasgow GIl 6NY; and 2CRC Department of Medical
Oncology, University of Glasgow, I Horselethill Road, Glasgow G12 9LX, UK.
Bone marrow toxicity is a major dose-limiting factor in the
clinical use ofadriamycin (doxorubicin) and VP16 (VP16-213,
etoposide). While the calcium antagonist verapamil has been
reported to enhance the sensitivity of a number of animal
(Tsuruo et al., 1982; Ramu et al., 1984; Yalowich & Ross,
1984; Tsuruo et al., 1985; Supino et al., 1986) and human
(Tsuruo et al., 1983a; Rogan et al., 1984; Merry et al.,
1986a, Merry et al., 1987; Slater et al., 1986; Twentyman et
al., 1986) tumours to these cytotoxic agents in vitro, the
effects of verapamil on the cytotoxic drug sensitivity of bone
marrow has not been extensively studied.
Using a clonogenic assay, we have studied the effect of
verapamil at a range of concentrations (including concen-
trations achievable in vivo) on the sensitivity of human bone
marrow granulocyte-macrophage stem cells (CFU-GM) to
adriamycin and VP16. Our findings are presented in this
short report.
Marrow was aspirated from patients with iron or B12/
folate deficiency, whose haemopoiesis could be normalised in
vitro. Marrow was spun over Ficoll-diatrizoate (SG 1.077) at
400g for 30min and light density marrow cells (LDMC's)
harvested from the interface. Cells were washed once in
RPMI-1640 (Gibco UK).
Lymphocyte conditioned medium was produced by light
density peripheral blood mononuclear cells (PBNCs) from
normal subjects obtained using Ficoll-diatrizoate separation
(as above). PBMNCs were adjusted to a concentration of
1 x 106Mml- in RPMI-1640 medium with HEPES and L-
glutamine (Gibco UK), 10% heat inactivated foetal calf
serum (Gibco UK) and 0.5% L-glutamine. Cell suspensions
were incubated at 37°C for 6 days in tissue culture flasks
(Nunclon, Denmark) in a 5% CO2 atmosphere and 98%
humidity with phytohaemagglutinin-P (Difco, UK) 0.75% v/v.
After incubation, supernatants were sterile filtered (Millex
0.22 pm filters, Millipore UK Ltd.), pooled, diluted 1:4 in
RPMI-1640 medium and stored at -20°C.
VP16 (Mol. wt 588.6) was obtained as a pure powder
from Dr Dale Stringfellow, Bristol Myers Co. Ltd., Syracuse,
USA. The drug was initially dissolved in 50% ethanol, then
diluted in normal saline. A solvent control with ethanol at
final concentration of 0.025% was included. Adriamycin
(Mol. wt 580) was obtained from Farmatalia, Carlo Erba
Ltd., Barnet, Herts and dissolved in saline. Verapamil (Mol.
wt 491.1) was obtained from Abbot Laboratories Ltd.,
Queensborough, Kent and diluted in saline.
LDMCs to be cultured were incubated with or without the
addition of drugs (Table I) for 1 h at 37°C in 2ml RPMI-
1640 medium. Post incubation cells were washed twice then
set up in semisolid culture at a concentration of
1 x 10 ml-1. The addition of lymphocyte conditioned
medium was obligatory for CFU-GM colony formation.
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LDMCs were cultured in supplemented Dulbecco's modified
Eagles MEM (Gibco UK) with 0.8% methyl cellulose
(4,000cp Fluka, UK), heat inactivated foetal calf serum and
L-glutamine (60%, 20% and 0.5% of final culture volume
respectively). The remaining volume comprised pooled,
diluted lymphocyte conditioned medium. Cultures were per-
formed in Multiwell dishes (Costar, Cambridge, Mass.,
USA) in quadruplicate. CFU-GM colonies were scored after
7 days incubation at 37°C in a humidified atmosphere of 5%
CO2. A colony was defined as containing 40 or more cells.
The results of our cloning experiments are shown in Table
I. A total of 10 bone marrow specimens were assayed.
In preliminary studies (subjects 5 and 6) colony number
was determined in the presence and absence of the solvent
used to dissolve the VP16 (i.e. 0.025% ethanol, final con-
centration). In each case no effect of solvent was noted and
in subsequent experiments only solvent-containing controls
were set up. The effect of verapamil alone on colony number
was also determined (8 cases at 6.6 uM, 4 cases at 3.3gM, 4
cases at 1.5uM and 8 cases at 0.66iM). In no instance was
colony number reduced by more than 10% compared to
solvent controls.
The bone marrow specimens exhibited a range of sensitivi-
ties in vitro to the concentrations of cytotoxic drugs used in
these studies. In the case of adriamycin, colony number was
reduced by between 24% and 78% (10 cases). For VP16
colony number was reduced between 19% and 76% (10
cases). The mean reduction in colony number was 56% for
adriamycin and 40% for VP16. Furthermore the bone
marrow specimens which showed the greatest sensitivity to
adriamycin (subjects 1, 3, 4, 6, 8 and 10) also showed the
greatest sensitivity to VP16.
Verapamil (at non-cytotoxic concentrations of 3.3-6.6jgM)
did enhance the sensitivity of human bone marrow CFU-
GM to adriamycin and VP16, but at the clinically relevant
doses of 0.66-1.5pM little effect was noted. Specifically, in
comparison to adriamycin treatment alone, colony number
was reduced more than 20% to 6.6jIM verapamil plus
adriamycin in 3/8 cases (subjects 4, 5 and 6); by 3.34uM
verapamil plus adriamycin in 2/4 cases (subjects 3 and 4); by
1.5pM verapamil plus adriamycin on 0/4 cases and by
0.66pM verapamil plus adriamycin in 0/8 cases. For VP16,
the corresponding results are 7/8 cases (subjects 1, 2, 3, 4, 5,
6, 7, 8 and 10) at 6.6pM verapamil; 3/4 cases (subjects 1, 3
and 4) at 3.3pM verapamil; 0/4 cases at 1.5,UM verapamil
and 1/8 cases (subject 10) at 0.66jIM verapamil. Furthermore
in some cases (subjects 1, 2 and 10) concentrations of
verapamil that enhanced sensitivity to VP16 did not do so
for adriamycin. Further experiments (using a more extensive
series of specimens and with a range of cytotoxic drug
concentrations) would be required to confirm the generality
of this latter observation.
There have been a limited number of previous studies of
the effect of verapamil on the sensitivity of human bone
marrow to cytotoxic drugs. Robinson et al. (1985) showed
that verapamil at a concentration of 23pM had no effect on
the sensitivity of human bone marrow to melphalan. Fine et
al. (1987) showed that 2.2pM verapamil did not enhance
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Table I Effects of adriamycin and VP16 with and without verapamil on human CFU-GM
Colonies per 5 x 104 cellsa
Subject 1 2 3 4 5 6 7 8 9 10
Solvent control 144+16 297+6 296+6 240+15 207+10 218+17 289+15 253+9 319+12 309+13
untreated b - 209+6 223+13
6.6uMVPMC 139+3 278+16 270+17 233+23 198+9 212+8
3.3gMVPM 130+15 293+1 267+17 223+5
1.5jMVPM 146+14 279+2 295+7 236+17 --
0.66,UMVPM 150+12 288+3 290+ 16 226+ 15 - - 284+ 13 257+ 14 301 + 11 301 + 19
0.6 tMADRd 33+5 177+35 91+15 57+8 154+10 75+9 144+8 121+9 199+3 130+10
0.6pMADR+6.6gMVPM 33+8 186+34 94+11 30+8 107+7 22+9 - 161+16 108+9
0.6,gMADR+3.3MVPM 40+4 171+34 68+5 33+3 - -
0.6gMADR+ 1.5gMVPM 32+4 178+39 93 + 13 65 + 17
0.6juMADR+0.661uMVPM 37+6 210+7 88+18 59+4 - 144+8 122+15 201+17 134+8
50!LMVP16 35+18 211+14 129+12 144+14 168+4 136+11 194+8 158+10 231+8 172+17
5OjiMVP16+6.6jiMVPM 14+6 166+6 71+11 108+55 115+12 89+14 - 204+15 101+5
50juMVP16+3.3 IMVPM 24+3 193+26 77+8 114+12 -
50pMVP16+1.5yMVPM 28+5 227+18 131+10 115+11 -
50,uMVP16+0.661uMVPM 37+5 215+16 134+10 153+6 200+9 164+20 237+6 100+4
aResults expressed as MEAN+s.d.; bIndicates colony number not determined; cVerapamil; dAdriamycin.
sensitivity to adriamycin or vinblastine and Yalowich et al.
(1985) showed that 2.5-40IM verapamil enhanced sensitivity
to VP16, but not to adriamycin and vincristine. Our data are
broadly in agreement with those of Fine et al. and with
those of Yalowich et al. for VP16, but conflict with Yalo-
wich's results for adriamycin. Since conditions of drug
treatment (1 h, 37°C) in this latter study were similar to our
own the different results are most likely due to differences in
the conditions used for cloning. Most notably, the use of
different colony stimulating factors may be important in the
selection of different populations to cells to grow to form
colonies.
While plasma levels of verapamil of up to 10juM may be
achieved clinically by intravenous infusion (Ozols et al.,
1984) these are associated with significant cardiovascular
toxicity. Recent clinical trials (Benson et al., 1985; Cantwell
et al., 1985) have however shown that steady state concent-
rations of verapamil in plasma of 0.5-1 fM can be main-
tained with limited toxicity. In the context of enhancement
of drug sensitivity this concentration of verapamil is at the
lower end of the dose-response curve, but some studies
(Yalowich & Ross, 1984; Slater et al., 1986; Supino et al.,
1986) do indicate that verapamil may enhance sensitivity to
adriamycin and VP16 at concentrations of 1-2pM in vitro.
These concentrations of verapamil in vitro have also been
reported to enhance tumour cell sensitivity to vinca alkaloids
(Tsuruo et al., 1981; Tsuruo et al., 1983a; Simmonds et al.,
1986) and daunorubicin (a structural analogue of adriamy-
cin; Slater et al., 1982).
In vivo, using animal ascites tumour models, verapamil has
been reported to enhance sensitivity to VP16 (Slater et al.,
1986), daunorubicin (Slater et al., 1982) and vincristine
(Tsuruo et al., 1981). In these studies drug treatment was
administered intraperitoneally. It is not yet known whether
enhancement of drug sensitivity in vivo by verapamil is a
general phenomenon for solid tumours, but preliminary data
indicate that it may be. Tsuruo et al. (1983b) have shown
that administration of vincristine plus verapamil increases
the survival of mice bearing colon adenocarcinoma growing
intraperitoneally compared to treatment with vincristine
alone. Furthermore verapamil has been reported to enhance
the sensitivity of a subcutaneously-growing murine fibrosar-
coma to melphalan (Robinson et al., 1985), of a human
neuroblastoma xenograft to cisplatinum (Ikeda et al., 1987)
and of human lung cancer xenograft to vincristine (Mattern
et al., 1987). Our preliminary data using human lung cancer
xenografts (Merry et al., 1986b) and the subcutaneously
growing murine Ridgeway osteogenic sarcoma (ROS; unpub-
lished) have also shown that verapamil is able to increase
sensitivity to VP16 and, in the case of the ROS tumour,
vincristine and actinomycin D. In this context it is important
to note that maximum plasma concentrations of 1.6,UM were
obtained in our xenograft study.
In summary, our data indicates that verapamil at concen-
trations of 0.66-1.5pM does not enhance the sensitivity of
human bone marrow CFU-GM to adriamycin and VP16.
Other reports have shown that (a) 1-2pM verapamil
enhances tumour sensitivity in vitro, (b) verapamil (at peak
plasma concentrations of 1.6,UM) enhances tumour sensitivity
in vivo and (c) plasma concentrations of 0.5-1 pM can be
maintained in humans with minimal toxicity. Verapamil may
therefore enhance cytotoxic drug sensitivity in tumour tissue
at clinically achievable concentrations without increasing
marrow toxicity. Clinical trials to determine the efficacy of
verapamil in overcoming tumour drug resistance would
appear to be justified. Our observations that human bone
marrow CFU-GM have a range of sensitivities to adriamycin
and VP16 and that, in some cases, sensitivity to VP16 is
enhanced at concentrations of verapamil which do not
enhance adriamycin sensitivity may also have important
clinical consequences; although further studies are required.
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